| Author | No. of Patients | Treatment received | Imaging Response | Adverse Events | Follow up |
| This study | 1 | 4 cycles of Lu-Dotatate and 4 cycles of Octreotide in 2020 followed by 20 cycles of octreotide maintenance | Partial | Fatigue, hyporexia, dysgeusia, Grade 1 alopecia | 18 months (alive with disease controlled) |
| Hasan [13] | 7 | 4 cycles of Lu-Dotatate and 111In-Octreotide in 2008. |
|
|
|
| In 2010 5FU and Lu-Dotatete | Partial | Transient phlebitis | 38 months | ||
| 3 cycles of Lu-Dotatate with 5FU in 2010 and 4 cycles of Lu-Dotatate in 2011 | Partial | Grade 2 thrombocytopenia | 53 months | ||
| 2 cycles of Lu-Dotatate in 2012 | Progression | Pneumonia, Grade 4 neutropenia | 4 months | ||
| 4 cycles of Lu-Dotatate with etoposide in 2017 | Stable | None | 33 months (alive) | ||
| 3 cycles of Lu-Dotatate in 2017 | Partial | Recurrence of cerebrospinal fluid leak | 20 months | ||
| 4 cycles in 2015 and 3 salvage cycles in 2017 of Lu-Dotatate | Partial | Weakness, transient grade 2 pancytopenia | 32 months | ||
| Sabongi [14] | 1 | 3 cycles of Lu-Dotatate and 4 cycles of octreotide in 2010 | Partial | Not described | (alive) |
| Makis [15] | 1 | 4 cycles of 111In-Octreotide followed by 3 cycles of Lu-Dotatate | Partial | Not described | 5 months |
| Schneider [16] | 1 | 4 cycles of Lu-Dotatate in 2016 And after relapse another 4 cycles | Partial | Not described | 13 months |